6334 Winfield Boulevard
215 articles with Synergy Pharmaceuticals
Company Initiates Voluntary Chapter 11 Process to Effectuate Sale; Secures Commitment for DIP Financing to Support Normal-Course Operations
Bausch Health Companies is acquiring basically all of Synergy Pharmaceuticals’ assets, including all rights to Trulance (plecanatide), dolcanatide and related intellectual property.
Synergy Pharmaceuticals Inc. today reported its financial results and business update for the three months ended September 30, 2018.
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Melvin K. Spigelman, M.D., who has served as an Independent Director of Synergy since August 2008, will now assume the role of Chairman of the Board, effective immediately.
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
Synergy Pharmaceuticals Inc. today provided a business update.
Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® (plecanatide) in Two Patient Populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting
New analyses results reinforce effectiveness and safety for the use of TRULANCE in adults with CIC or IBS-C
Synergy Pharmaceuticals to Present New Analyses of TRULANCE® (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting
New analyses further reinforce effectiveness and safety in important subpopulations of adults with CIC or IBS-C
Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access Wins
Several new formulary wins improve TRULANCE 2018 and 2019 coverage status across major U.S. Commercial, Medicare Part D and Managed Medicaid plans.
CORRECTING and REPLACING Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update
CORRECTION...by Synergy Pharmaceuticals Inc.
TRULANCE® second quarter net sales up over 40% versus prior quarter
Synergy Pharmaceuticals Announces TRULANCE® (plecanatide) Added to Express Scripts 2019 National Preferred Formulary List
Synergy Pharmaceuticals Inc. announced that leading U.S. pharmacy benefit manager, Express Scripts, will add TRULANCE to its National Preferred Formulary List, effective January 1, 2019.
Synergy Pharmaceuticals Announces License Agreement with Luoxin Pharmaceutical Group for TRULANCE® (plecanatide) in China
Synergy Pharmaceuticals Inc. announced that the company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin) providing Luoxin exclusive rights to develop and commercialize Synergy’s lead product TRULANCE® (plecanatide)
Synergy Pharmaceuticals Inc. today announced that it has received a waiver to extend the draw down date of the second borrowing under its Term Loan Agreement with CRG LP.
Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C)
Synergy Pharmaceuticals Inc. announced new data presented at Digestive Disease Week (DDW) 2018 showing chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) are associated with depressed levels of uroguanylin, a naturally occurring and endogenous human GI peptide.
Synergy Pharmaceuticals to Present New Analysis of Therapeutic Risk and Benefit of TRULANCE® (plecanatide) and Linaclotide in Chronic Idiopathic Constipation (CIC) Patients at Digestive Disease Week (DDW)
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the company will present a new risk/benefit analysis from pooled Phase 3 study data evaluating TRULANCE® (plecanatide) and linaclotide for the treatment of adults with chronic idiopathic constipation (CIC).
Synergy Pharmaceuticals Inc. announced three abstracts that will be presented at Digestive Disease Week (DDW) in Washington D.C. June 2-5, 2018.
TRULANCE only CIC/IBS-C Rx brand to grow in total and new Rx volume quarter-over-quarter, per IQVIA Synergy lowers 2018 adjusted operating expense (non-GAAP) guidance
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Troy Hamilton, Chief Executive Officer of Synergy, will present a corporate update at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern Time at the Westin New York Grand Central in New York City.
Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update
TRULANCE® U.S. net sales were $9.4 million in the fourth quarter, totaling $16.8 million for 2017.